Table 1.
Results of Clinical Data Targeting HER2 Aberrations Among Lung Cancer Patients Reported in Various Trials
| Drug | Author(Year) | Trial | HER2 Aberrations | No. Patients | ORR (%) | mPFS (m) | mOS (m) | DoR (m) | Sensitive HER2 Subtype |
|---|---|---|---|---|---|---|---|---|---|
| Afatinib | De Greve et al (2015)36 | Retrospective | HER mutation | 7 | 0 | 4.25 | NA | 4 | NA |
| Ou et al (2017)27 | Retrospective | HER2 mutation | 15 | 27(4/15) | NA | NA | NA | NA | |
| Liu Z et al (2016)31 | Retrospective | HER2 ex20ins | 19 | 15.8(3/19) | 4.5 | 11.5 | NA | HER2G778_P780dup | |
| Peters S et al (2018)35 | Retrospective | HER2 ex20ins | 28 | 19 (3/16) | NA | NA | 9.6 | HER2YVMA | |
| Dziadziuszko R et al (2019)33 | Phase II trial | HER2 ex20ins | 13 | 7.7(1/13) | 3.7 | 13.1 | NA | HER2YVMA | |
| Fang W et al (2019)25 | Retrospective | HER2 ex20ins | 32 | 15.6(5/32) | 3.2 | NA | NA | HER2G778_P780dup, HER2G776delinsVC | |
| Lai et al (2018)34 | Retrospective | HER2 ex20ins, HER2V659E (ex17) HER2S310F (ex8) |
27 | 13(3/23) | NA | 7 | 3 | HER2ex20ins | |
| Neratinib | Hyman DM et al (2018)39 | Phase II trial | HER2 ex20ins HER2S310F(ex8) HER2L755S(ex19) |
26 | 3.8(1/26) | 5.5 | NA | NA | HER2ex20ins |
| Pozitinib | Robichaux et al (2018)42 | Phase I/II trial | HER2 ex20ins | 12 | 42(5/12) | 5.6 | NA | 4.6 | HER2YVMA HER2G778_P780dup |
| Dacomtinib | Kris et al(2015)44 | Phase II trial | HER2 ex20ins | 26 | 12(3/26) | 4 | 9 | NA | HER2G778_P780dup |
| HER2 amplification | 4 | 0 | 1,1,5,5 | 5,7,15,22 | NA | NA | |||
| Pyrotinib | Wang Y et al (2019)45 | Phase II trial | HER2 ex20ins | 15 | 53.3 | 6.4 | 12.9 | 7.2 | HER2ex20ins |
| Zhou C et al (2020)46 | Phase II trial | HER2 ex20ins | 60 | 31.7(19/60) | NA | NA | 1.0 | HER2ex20ins | |
| TAK-778(Mobocertinib) | Gonzalvez F et al(2020) (AACR 2020) |
EGFR ex20ins HER2 ex20ins |
60 | 34.78(21/60) | NA | NA | NA | NA | |
| Trastuzumab +Pertuzumab | Hainsworth et al (2018)50 | Phase IIa trial | HER2 mutation | 14 | 21(3/14) | NA | NA | NA | NA |
| HER2 overexpress or amplification | 16 | 13(2/16) | NA | NA | NA | NA | |||
| T-DM1 | Peters S et al (2019)82 | Phase II trial | HER overexpression 2+ | 29 | 0 | 2.6 | 12.2 | NA | NA |
| HER overexpression 3+ | 20 | 20% | 2.7 | 12.1 | NA | NA | |||
| Li BT et al (2018)52 | Phase II trial | HER2 mutations | 18 | 44(8/18) | 5 | NA | 4 | NA | |
| DS8201 | Tsurutani J et al(2020)55 | Phase I trial | HER2 mutations | 11 | 88.2 | 14.1 | NA | NA | NA |
| HER2 overexpression (2+ or 3+) | 18 | 58.5 | 14.1 | NA | NA | NA | |||
| Smit EF et al (2020)56 | Phase II trial | HER2 mutations | 42 | 61.9 | 14 | NA | NA | NA |